Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
Our transformative product candidates - best in class - Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology.
Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients. In order to fully exploit the potential of Immatics' product pipeline and technologies we invite others to join us on this exciting mission.
Contact Us about Partnering Opportunities
Immatics Biotechnologies GmbH
Business Development Group